The chemical industry is comprised of three major segments: commodity, specialty and fine chemicals. Combined annual sales in these three segments exceeded US$1.5 trillion in 2000. Industry experts estimate that within the next decade biological processes will be used to make a variety of chemicals with combined annual revenues in excess of US$50 billion dollars.

Dyadic expects to utilize its C1 integrated technology platform to help enable the discovery, development and manufacture of high performance enzymes that may increase manufacturing yield, decrease the costs of known processes, or accelerate the development of new chemical products.

Dyadic believes that its core competencies will help enable novel biological processes, for example, either by fermentation or through the use of enzyme catalysts.

Dyadic is intent on becoming the global leader in providing proprietary biologically-based process solutions for the discovery and manufacture of bulk, specialty and fine chemicals, including pharmaceutical intermediates and products. Included in the potential chemicals market is the manufacturing of major chemicals, plastics, resins, vitamins, and compounds used in the manufacture of pharmaceuticals, enzymes for use as catalysts, and polymers and fibers for use in textiles.

Dyadic’s business strategy utilizes its integrated C1 technology platform to discover, develop and manufacture novel biomolecules derived from the earth’s gene pool with leaders in relevant segments of the chemical industry, ranging from commodity to high-end pharmaceutical intermediates.